189 related articles for article (PubMed ID: 37172199)
21. IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells.
Schinke C; Giricz O; Li W; Shastri A; Gordon S; Barreyro L; Bhagat T; Bhattacharyya S; Ramachandra N; Bartenstein M; Pellagatti A; Boultwood J; Wickrema A; Yu Y; Will B; Wei S; Steidl U; Verma A
Blood; 2015 May; 125(20):3144-52. PubMed ID: 25810490
[TBL] [Abstract][Full Text] [Related]
22. Helical assembly in the MyD88-IRAK4-IRAK2 complex in TLR/IL-1R signalling.
Lin SC; Lo YC; Wu H
Nature; 2010 Jun; 465(7300):885-90. PubMed ID: 20485341
[TBL] [Abstract][Full Text] [Related]
23. A small molecule potent IRAK4 inhibitor abrogates lipopolysaccharide-induced macrophage inflammation in-vitro and in-vivo.
Choudhary SA; Patra D; Sinha A; Mazumder S; Pant R; Chouhan R; Jha AN; Prusty BM; Manna D; Das SK; Tikoo K; Pal D; Dasgupta S
Eur J Pharmacol; 2023 Apr; 944():175593. PubMed ID: 36804543
[TBL] [Abstract][Full Text] [Related]
24. Molecular characterization and expression analyses of five genes involved in the MyD88-dependent pathway of yellow catfish (Pelteobagrus fulvidraco) responding to challenge of Aeromonas hydrophila.
Yuan Y; Shi Z; Wang Q; Guo M; Yuan L; Zhao Z; Liu S; Wu C; Sun R; Wang B; Ouyang G; Ji W
Fish Shellfish Immunol; 2023 Jun; 137():108712. PubMed ID: 37030559
[TBL] [Abstract][Full Text] [Related]
25. IRAK1 and IRAK4 as emerging therapeutic targets in hematologic malignancies.
Bennett J; Starczynowski DT
Curr Opin Hematol; 2022 Jan; 29(1):8-19. PubMed ID: 34743084
[TBL] [Abstract][Full Text] [Related]
26. Functional assessment of the mutational effects of human IRAK4 and MyD88 genes.
Yamamoto T; Tsutsumi N; Tochio H; Ohnishi H; Kubota K; Kato Z; Shirakawa M; Kondo N
Mol Immunol; 2014 Mar; 58(1):66-76. PubMed ID: 24316379
[TBL] [Abstract][Full Text] [Related]
27. Pivotal Advance: Inhibition of MyD88 dimerization and recruitment of IRAK1 and IRAK4 by a novel peptidomimetic compound.
Loiarro M; Capolunghi F; Fantò N; Gallo G; Campo S; Arseni B; Carsetti R; Carminati P; De Santis R; Ruggiero V; Sette C
J Leukoc Biol; 2007 Oct; 82(4):801-10. PubMed ID: 17548806
[TBL] [Abstract][Full Text] [Related]
28. Selective interleukin-1 receptor-associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy.
Kelly PN; Romero DL; Yang Y; Shaffer AL; Chaudhary D; Robinson S; Miao W; Rui L; Westlin WF; Kapeller R; Staudt LM
J Exp Med; 2015 Dec; 212(13):2189-201. PubMed ID: 26621451
[TBL] [Abstract][Full Text] [Related]
29. Identification of optineurin as an interleukin-1 receptor-associated kinase 1-binding protein and its role in regulation of MyD88-dependent signaling.
Tanishima M; Takashima S; Honda A; Yasuda D; Tanikawa T; Ishii S; MaruYama T
J Biol Chem; 2017 Oct; 292(42):17250-17257. PubMed ID: 28882891
[TBL] [Abstract][Full Text] [Related]
30. Cloning and functional characterization of IRAK4 in large yellow croaker (Larimichthys crocea) that associates with MyD88 but impairs NF-κB activation.
Zou PF; Huang XN; Yao CL; Sun QX; Li Y; Zhu Q; Yu ZX; Fan ZJ
Fish Shellfish Immunol; 2017 Apr; 63():452-464. PubMed ID: 27989863
[TBL] [Abstract][Full Text] [Related]
31. Cutting edge: TLR signaling licenses IRAK1 for rapid activation of the NLRP3 inflammasome.
Fernandes-Alnemri T; Kang S; Anderson C; Sagara J; Fitzgerald KA; Alnemri ES
J Immunol; 2013 Oct; 191(8):3995-9. PubMed ID: 24043892
[TBL] [Abstract][Full Text] [Related]
32. Targeting Immune Signaling Pathways in Clonal Hematopoiesis.
Azrakhsh NA; Mensah-Glanowska P; Sand K; Kittang AO
Curr Med Chem; 2019; 26(28):5262-5277. PubMed ID: 30907306
[TBL] [Abstract][Full Text] [Related]
33. Design and synthesis of Imidazo[1,2-b]pyridazine IRAK4 inhibitors for the treatment of mutant MYD88 L265P diffuse large B-cell lymphoma.
Chen Y; Bai G; Ning Y; Cai S; Zhang T; Song P; Zhou J; Duan W; Ding J; Xie H; Zhang H
Eur J Med Chem; 2020 Mar; 190():112092. PubMed ID: 32014679
[TBL] [Abstract][Full Text] [Related]
34. IRAK1 Augments Cancer Stemness and Drug Resistance via the AP-1/AKR1B10 Signaling Cascade in Hepatocellular Carcinoma.
Cheng BY; Lau EY; Leung HW; Leung CO; Ho NP; Gurung S; Cheng LK; Lin CH; Lo RC; Ma S; Ng IO; Lee TK
Cancer Res; 2018 May; 78(9):2332-2342. PubMed ID: 29483095
[TBL] [Abstract][Full Text] [Related]
35. Pericyte MyD88 and IRAK4 control inflammatory and fibrotic responses to tissue injury.
Leaf IA; Nakagawa S; Johnson BG; Cha JJ; Mittelsteadt K; Guckian KM; Gomez IG; Altemeier WA; Duffield JS
J Clin Invest; 2017 Jan; 127(1):321-334. PubMed ID: 27869651
[TBL] [Abstract][Full Text] [Related]
36. FADD negatively regulates lipopolysaccharide signaling by impairing interleukin-1 receptor-associated kinase 1-MyD88 interaction.
Zhande R; Dauphinee SM; Thomas JA; Yamamoto M; Akira S; Karsan A
Mol Cell Biol; 2007 Nov; 27(21):7394-404. PubMed ID: 17785432
[TBL] [Abstract][Full Text] [Related]
37. Suppression of the DNA damage response in acute myeloid leukemia versus myelodysplastic syndrome.
Boehrer S; Adès L; Tajeddine N; Hofmann WK; Kriener S; Bug G; Ottmann OG; Ruthardt M; Galluzzi L; Fouassier C; Tailler M; Olaussen KA; Gardin C; Eclache V; de Botton S; Thepot S; Fenaux P; Kroemer G
Oncogene; 2009 Jun; 28(22):2205-18. PubMed ID: 19398952
[TBL] [Abstract][Full Text] [Related]
38. Mesenchymal stromal cells from myelodysplastic and acute myeloid leukemia patients display in vitro reduced proliferative potential and similar capacity to support leukemia cell survival.
Corradi G; Baldazzi C; Očadlíková D; Marconi G; Parisi S; Testoni N; Finelli C; Cavo M; Curti A; Ciciarello M
Stem Cell Res Ther; 2018 Oct; 9(1):271. PubMed ID: 30359303
[TBL] [Abstract][Full Text] [Related]
39. Establishing and Validating Cellular Functional Target Engagement Assay for Selective IRAK4 Inhibitor Discovery.
Chen Y; Sun D; Yang R; Lim J; Sondey C; Presland J; Rakhilina L; Addona G; Kariv I; Chen H
SLAS Discov; 2021 Sep; 26(8):1040-1054. PubMed ID: 34130529
[TBL] [Abstract][Full Text] [Related]
40. Modulating the immune system as a therapeutic target for myelodysplastic syndromes and acute myeloid leukemia.
Putnam C; Kondeti L; Kesler M; Varney M
Biochem Cell Biol; 2023 Dec; 101(6):481-495. PubMed ID: 37566901
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
